Role of thromboxane-dependent platelet activation in venous thrombosis: Aspirin effects in mouse model

Eva Tarantino, Patrizia Amadio, Isabella Squellerio, Benedetta Porro, Leonardo Sandrini, Linda Turnu, Viviana Cavalca, Elena Tremoli, Silvia S. Barbieri

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Recent trials suggest that Aspirin (ASA) reduces the incidence of venous thromboembolism in human. However, the molecular mechanisms underlying this effect are still unclear. In this study we assessed the effects of ASA in venous thrombosis mouse model induced by inferior vena cava (IVC) ligation and we investigated the mechanisms responsible for this effect. ASA (3 mg/kg daily for 2 days) treatment decreased the thrombus size, the amounts of tissue factor activity in plasma microvesicles (TF-MP) and the levels of 2,3-dinor Thromboxane B2 (TXB-M) in urine compared to control mice. Interestingly, the thrombus size positively correlated with both TF-MP activity and TXB-M. In addition, positive correlation was observed between TF-MP activity and TXB-M. A reduced number of neutrophils and monocytes, and of TF-positive cells accompanied to a lower amount of fibrin and neutrophil extracellular traps (NETs) were also found in thrombi of ASA-treated mice. Similar results were obtained when mice were treated 24 h before IVC ligation with SQ29548 (1 mg/kg), a selective thromboxane receptor antagonist. In addition, transfusion of platelets in SQ29548 treated-mice excluded the likelihood of a redundant role of platelet-TP receptor in this context. Finally, incubation of macrophages and neutrophils with SQ29548 prevented TF activity and/or NETs formation induced by supernatant of activated platelets or by IBOP, a selective thromboxane analogue. In conclusion, ASA, suppressing TXA2, prevents macrophages and neutrophils activation and markedly reduces thrombus size with a mechanism most likely dependent of the inhibition of TF activity and NETs formation. These results provide a new link between platelet-produced thromboxane and the occurrence of venous thrombosis.

Original languageEnglish
Pages (from-to)415-425
Number of pages11
JournalPharmacological Research
Volume107
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Thromboxanes
Platelet Activation
Venous Thrombosis
Aspirin
Thrombosis
Thromboxane Receptors
Blood Platelets
Inferior Vena Cava
Ligation
Neutrophils
Platelet Transfusion
Neutrophil Activation
Macrophage Activation
Venous Thromboembolism
Thromboplastin
Fibrin
Monocytes
Macrophages
Urine
Incidence

Keywords

  • Aspirin
  • NETs
  • Thromboxane
  • Tissue factor
  • Venous thrombosis

ASJC Scopus subject areas

  • Pharmacology

Cite this

Role of thromboxane-dependent platelet activation in venous thrombosis : Aspirin effects in mouse model. / Tarantino, Eva; Amadio, Patrizia; Squellerio, Isabella; Porro, Benedetta; Sandrini, Leonardo; Turnu, Linda; Cavalca, Viviana; Tremoli, Elena; Barbieri, Silvia S.

In: Pharmacological Research, Vol. 107, 01.05.2016, p. 415-425.

Research output: Contribution to journalArticle

@article{e423dd4714a549529c14f27259d8822a,
title = "Role of thromboxane-dependent platelet activation in venous thrombosis: Aspirin effects in mouse model",
abstract = "Recent trials suggest that Aspirin (ASA) reduces the incidence of venous thromboembolism in human. However, the molecular mechanisms underlying this effect are still unclear. In this study we assessed the effects of ASA in venous thrombosis mouse model induced by inferior vena cava (IVC) ligation and we investigated the mechanisms responsible for this effect. ASA (3 mg/kg daily for 2 days) treatment decreased the thrombus size, the amounts of tissue factor activity in plasma microvesicles (TF-MP) and the levels of 2,3-dinor Thromboxane B2 (TXB-M) in urine compared to control mice. Interestingly, the thrombus size positively correlated with both TF-MP activity and TXB-M. In addition, positive correlation was observed between TF-MP activity and TXB-M. A reduced number of neutrophils and monocytes, and of TF-positive cells accompanied to a lower amount of fibrin and neutrophil extracellular traps (NETs) were also found in thrombi of ASA-treated mice. Similar results were obtained when mice were treated 24 h before IVC ligation with SQ29548 (1 mg/kg), a selective thromboxane receptor antagonist. In addition, transfusion of platelets in SQ29548 treated-mice excluded the likelihood of a redundant role of platelet-TP receptor in this context. Finally, incubation of macrophages and neutrophils with SQ29548 prevented TF activity and/or NETs formation induced by supernatant of activated platelets or by IBOP, a selective thromboxane analogue. In conclusion, ASA, suppressing TXA2, prevents macrophages and neutrophils activation and markedly reduces thrombus size with a mechanism most likely dependent of the inhibition of TF activity and NETs formation. These results provide a new link between platelet-produced thromboxane and the occurrence of venous thrombosis.",
keywords = "Aspirin, NETs, Thromboxane, Tissue factor, Venous thrombosis",
author = "Eva Tarantino and Patrizia Amadio and Isabella Squellerio and Benedetta Porro and Leonardo Sandrini and Linda Turnu and Viviana Cavalca and Elena Tremoli and Barbieri, {Silvia S.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.phrs.2016.04.001",
language = "English",
volume = "107",
pages = "415--425",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",

}

TY - JOUR

T1 - Role of thromboxane-dependent platelet activation in venous thrombosis

T2 - Aspirin effects in mouse model

AU - Tarantino, Eva

AU - Amadio, Patrizia

AU - Squellerio, Isabella

AU - Porro, Benedetta

AU - Sandrini, Leonardo

AU - Turnu, Linda

AU - Cavalca, Viviana

AU - Tremoli, Elena

AU - Barbieri, Silvia S.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Recent trials suggest that Aspirin (ASA) reduces the incidence of venous thromboembolism in human. However, the molecular mechanisms underlying this effect are still unclear. In this study we assessed the effects of ASA in venous thrombosis mouse model induced by inferior vena cava (IVC) ligation and we investigated the mechanisms responsible for this effect. ASA (3 mg/kg daily for 2 days) treatment decreased the thrombus size, the amounts of tissue factor activity in plasma microvesicles (TF-MP) and the levels of 2,3-dinor Thromboxane B2 (TXB-M) in urine compared to control mice. Interestingly, the thrombus size positively correlated with both TF-MP activity and TXB-M. In addition, positive correlation was observed between TF-MP activity and TXB-M. A reduced number of neutrophils and monocytes, and of TF-positive cells accompanied to a lower amount of fibrin and neutrophil extracellular traps (NETs) were also found in thrombi of ASA-treated mice. Similar results were obtained when mice were treated 24 h before IVC ligation with SQ29548 (1 mg/kg), a selective thromboxane receptor antagonist. In addition, transfusion of platelets in SQ29548 treated-mice excluded the likelihood of a redundant role of platelet-TP receptor in this context. Finally, incubation of macrophages and neutrophils with SQ29548 prevented TF activity and/or NETs formation induced by supernatant of activated platelets or by IBOP, a selective thromboxane analogue. In conclusion, ASA, suppressing TXA2, prevents macrophages and neutrophils activation and markedly reduces thrombus size with a mechanism most likely dependent of the inhibition of TF activity and NETs formation. These results provide a new link between platelet-produced thromboxane and the occurrence of venous thrombosis.

AB - Recent trials suggest that Aspirin (ASA) reduces the incidence of venous thromboembolism in human. However, the molecular mechanisms underlying this effect are still unclear. In this study we assessed the effects of ASA in venous thrombosis mouse model induced by inferior vena cava (IVC) ligation and we investigated the mechanisms responsible for this effect. ASA (3 mg/kg daily for 2 days) treatment decreased the thrombus size, the amounts of tissue factor activity in plasma microvesicles (TF-MP) and the levels of 2,3-dinor Thromboxane B2 (TXB-M) in urine compared to control mice. Interestingly, the thrombus size positively correlated with both TF-MP activity and TXB-M. In addition, positive correlation was observed between TF-MP activity and TXB-M. A reduced number of neutrophils and monocytes, and of TF-positive cells accompanied to a lower amount of fibrin and neutrophil extracellular traps (NETs) were also found in thrombi of ASA-treated mice. Similar results were obtained when mice were treated 24 h before IVC ligation with SQ29548 (1 mg/kg), a selective thromboxane receptor antagonist. In addition, transfusion of platelets in SQ29548 treated-mice excluded the likelihood of a redundant role of platelet-TP receptor in this context. Finally, incubation of macrophages and neutrophils with SQ29548 prevented TF activity and/or NETs formation induced by supernatant of activated platelets or by IBOP, a selective thromboxane analogue. In conclusion, ASA, suppressing TXA2, prevents macrophages and neutrophils activation and markedly reduces thrombus size with a mechanism most likely dependent of the inhibition of TF activity and NETs formation. These results provide a new link between platelet-produced thromboxane and the occurrence of venous thrombosis.

KW - Aspirin

KW - NETs

KW - Thromboxane

KW - Tissue factor

KW - Venous thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84962916628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962916628&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2016.04.001

DO - 10.1016/j.phrs.2016.04.001

M3 - Article

AN - SCOPUS:84962916628

VL - 107

SP - 415

EP - 425

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -